OncoMatch/Clinical Trials/NCT06836492

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Is NCT06836492 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies VAC，VAC/VII，CAV/IE for rhabdomyosarcoma.

Phase 3RecruitingYizhuo ZhangNCT06836492Data as of May 2026

Treatment: VAC，VAC/VII，CAV/IE — The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Check if I qualify

Extracted eligibility criteria

Cancer type

Rhabdomyosarcoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify